PureTech Health plc Admission To Trading On The London Stock Exchange

PureTech Health plc ("PureTech" or the "Company"), a science-driven healthcare company seeking to solve some of the toughest health challenges in disruptive ways, announces that, further to its announcements on 19 June 2015, its entire issued ordinary share capital of 227,248,008 ordinary shares of one pence each has today been admitted to the premium listing segment of the Official List of the UK Listing Authority and to trading on the London Stock Exchange's main market for listed securities under the ticker "PRTC".

Total voting rights

In accordance with the Disclosure and Transparency Rules (DTR 5.6), the Company makes the following disclosure with respect to the share capital and voting rights of the Company. As at 24 June 2015, the share capital of the Company consists of 227,248,008 ordinary shares of one pence each with voting rights ("Shares"). The Company does not hold any shares in treasury. Therefore, the total number of shares and voting rights in the Company is 227,248,008.

The above figure (227,248,008) may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Enquiries:

PureTech

Daphne Zohar, Chief Executive Officer

Stephen Muniz, Executive Vice President, Legal, Finance and Operations
+1 617 456 0032
Jefferies International Limited (Global Coordinator, Sole Sponsor and Joint Bookrunner)
Simon Hardy
Graham Hertrich
Lee Morton
Gil Bar-Nahum
Christopher Binks
+44 (0) 20 7029 8000
Peel Hunt LLP (Joint Bookrunner)
Clare Terlouw
Jock Maxwell Macdonald
Oliver Jackson
+44 (0) 20 7418 8900
FTI Consulting (Communications adviser to PureTech)
Ben Atwell
Matthew Cole
+44 (0) 20 3727 1000

Notes to Editors

About PureTech
PureTech is a science-driven healthcare company, seeking to solve some of today’s toughest health challenges in disruptive ways. PureTech generates unconventional ideas, rigorously tests them, and builds businesses around potentially disruptive solutions with the aim to address significant unmet healthcare needs. PureTech has a proactive, theme-driven approach to creating innovative healthcare solutions, typically rooted in academic research and vetted by a network of experts with experience across multiple disciplines. PureTech currently has 12 operating companies which are actively developing product candidates designed to address significant markets in healthcare.

PureTech engages and collaborates with leading scientists across disciplines to source and evaluate a broad range of technologies in the selected theme to identify, validate and develop high impact technologies. This established model enables PureTech to take a broad, solution-agnostic and international view of a significant number of technologies in a particular theme, allowing PureTech's evaluation to be driven by a strong science and technology rigour. PureTech's theme-driven company creation process combines approaches from disparate fields, which the Directors believe offers PureTech a competitive advantage as the healthcare landscape rapidly changes as a result of the convergence of new technologies and participation by non-healthcare corporate entities.

Help employers find you! Check out all the jobs and post your resume.

Back to news